FDA launches priority vouchers for neglected-disease drugs.
Waltz
Emily
E
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000494:pharmacology / Q000627:therapeutic use; D001709:Biotechnology / Q000191:economics / Q000331:legislation & jurisprudence*; D009033:Culicidae / Q000469:parasitology; D017277:Drug Approval; D004338:Drug Combinations; D055808:Drug Discovery; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use; D005449:Fluorenes / Q000494:pharmacology / Q000627:therapeutic use; D006291:Health Policy; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000469:parasitology / Q000635:transmission; D009965:Orphan Drug Production / Q000191:economics / Q000331:legislation & jurisprudence*; D010961:Plasmodium / Q000187:drug effects; D014330:Tropical Medicine; D014481:United States; D014486:United States Food and Drug Administration
D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes